Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Acadia, Astrazeneca, Daiichi Sankyo, Medtronic, Promega, Quanterix, Relay, Revealdx, Zeiss.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Alto, Applied, Cycle, Eli Lilly, Hookipa, Illumina, Insilico, Menarini, Meiragtx, Neotrail, Newron, Owlet, Pacbio, Prophase, Setpoint, Stemline, WebAI, Zipbio, Zonsen.
Clinical updates for biopharma and med tech, including data readouts and publications: Alzheon, Avacta, Endospan, Inspira, NMD, Novo Nordisk, Olympus, Persica, Pfizer, Sagimet, Ultragenyx, Volta.
Biopharma and med-tech companies raising money in public or private financings, including: Adlai Nortye, Medx, Polaryx, Salspera, Sangamo, Sonovascular, Vaxcyte.
New hires and promotions in the biopharma and med-tech industries, including: Aptevo, B. Braun, Bicycle, Bioivt, CDR-Life, Hemostemix, Immorta, Kupando, Kyverna, Leonabio, Metabolon, Pyxis, Rigel, Spruce, Valo, Zelluna.
CD122 – shared beta subunit of the IL-15 and IL-2 receptors, two targets for the figurative price of one – has drawn the eyes of many drug developers, among them Anaptysbio Inc., which will roll out phase Ib results in celiac disease during the fourth quarter of this year with ANB-033. The San Diego-based firm intends to weigh the candidate in a second inflammatory disease. A phase Ib study with ANB-033 in eosinophilic esophagitis will begin this quarter.
RSS
